In the first quarter of 2020, Revance entered into a distribution agreement with TEOXANE SA making Revance the exclusive commercialization partner of the company’s innovative RHA® Collection – resilient hyaluronic acid. Under the distribution agreement, Revance gained immediate and exclusive rights to commercialize the RHA® Collection of dermal fillers in the U.S., starting with the FDA-approved RHA® 2, RHA® 3, and RHA® 4 products, which include lidocaine. The agreement also includes a fourth product, RHA® 1, currently in clinical trials in the U.S. with FDA approval anticipated in 2021, and includes an ongoing collaboration with TEOXANE SA for a robust pipeline of additional indications and next-generation dermal filler technologies. Additionally, the agreement contains a right of first negotiation to access TEOXANE’s novel cosmeceutical line that incorporates its propriety RHA® technology.
In partnership with Viatris Inc. (formerly known as Mylan N.V.), Revance is developing a biosimilar to BOTOX®, which would allow Revance to compete in the existing short-acting neuromodulator marketplace, while focusing commercial efforts on creating a new, longer-acting neuromodulator category.
BOTOX® is a registered trademark of Allergan, Inc.
China Market License
We entered into a license agreement with Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd., (Fosun Pharma Industrial), a wholly-owned subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (Fosun Pharma), providing Fosun Pharma Industrial with the exclusive rights to develop and commercialize our proprietary DaxibotulinumtoxinA for Injection in mainland China, Hong Kong and Macau (the Territory).
If you are interested in pursuing a corporate partnership please contact us by filling out the form below:
DaxibotulinumtoxinA for Injection is an investigational agent that has not been approved by the FDA and is currently under regulatory review.